BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34607954)

  • 1.
    He Y; Rivera J; Diossy M; Duan H; Bowman-Colin C; Reed R; Jennings R; Novak J; Tran SV; Cohen EF; Szuts D; Giobbie-Hurder A; Bronson RT; Bass AJ; Signoretti S; Szallasi Z; Livingston DM; Pathania S
    Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34607954
    [No Abstract]   [Full Text] [Related]  

  • 2. A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.
    Liu Y; Yen HY; Austria T; Pettersson J; Peti-Peterdi J; Maxson R; Widschwendter M; Dubeau L
    EBioMedicine; 2015 Oct; 2(10):1318-30. PubMed ID: 26629527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach.
    Cao L; Xu X; Cao LL; Wang RH; Coumoul X; Kim SS; Deng CX
    Carcinogenesis; 2007 Jul; 28(7):1401-7. PubMed ID: 17363841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.
    Wistuba II; Tomlinson GE; Behrens C; Virmani A; Geradts J; Blum JL; Minna JD; Gazdar AF
    Genes Chromosomes Cancer; 2000 Aug; 28(4):359-69. PubMed ID: 10862044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
    Werness BA; Parvatiyar P; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; DiCioccio RA; Wiest J; Tsukada Y; Ponder BA; Piver MS
    J Natl Cancer Inst; 2000 Jul; 92(13):1088-91. PubMed ID: 10880552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice.
    Cressman VL; Backlund DC; Avrutskaya AV; Leadon SA; Godfrey V; Koller BH
    Mol Cell Biol; 1999 Oct; 19(10):7061-75. PubMed ID: 10490643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.
    Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR
    Differentiation; 2009 Jan; 77(1):103-11. PubMed ID: 19281769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
    Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
    PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zinc deficiency potentiates induction and progression of lingual and esophageal tumors in p53-deficient mice.
    Fong LY; Jiang Y; Farber JL
    Carcinogenesis; 2006 Jul; 27(7):1489-96. PubMed ID: 16543248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
    Xu X; Qiao W; Linke SP; Cao L; Li WM; Furth PA; Harris CC; Deng CX
    Nat Genet; 2001 Jul; 28(3):266-71. PubMed ID: 11431698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
    Triplett AA; Montagna C; Wagner KU
    Neoplasia; 2008 Dec; 10(12):1325-34. PubMed ID: 19048111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.
    Upton DH; Fuller ES; Colvin EK; Walters KA; Jimenez M; Desai R; Handelsman DJ; Howell VM; Allan CM
    Horm Cancer; 2015 Aug; 6(4):142-52. PubMed ID: 25943777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esophageal Squamous Cancer from 4NQO-Induced Mice Model: CNV Alterations.
    Liu Z; Su R; Ahsan A; Liu C; Liao X; Tian D; Su M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
    Jeng YM; Cai-Ng S; Li A; Furuta S; Chew H; Chen PL; Lee EY; Lee WH
    Oncogene; 2007 Sep; 26(42):6160-6. PubMed ID: 17420720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations.
    Saeki H; Kitao H; Yoshinaga K; Nakanoko T; Kubo N; Kakeji Y; Morita M; Maehara Y
    Clin Cancer Res; 2011 Apr; 17(7):1731-40. PubMed ID: 21325068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
    Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
    Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
    Xing D; Orsulic S
    Cancer Res; 2006 Sep; 66(18):8949-53. PubMed ID: 16982732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.